# Anirudh Joshi

> Anirudh Joshi is the co-founder and CEO of Valar Labs, a Palo Alto-based AI oncology company building tools that let doctors predict whether a specific cancer treatment will work before a patient wastes months on the wrong one. A biomedical engineer trained at Georgia Tech and Stanford, he previously built AI at Microsoft, PathAI, and Curai before co-founding Valar in 2021 with teammates from Stanford's AI in Medicine group. Valar raised $26M total, landing a $22M Series A from Andreessen Horowitz and DCVC in 2024, and its flagship test Vesta — predicting BCG therapy response in bladder cancer — is now live at 20 U.S. hospitals. Named to Forbes 30 Under 30 Healthcare 2025.

- **Role:** Co-Founder and CEO at Valar Labs
- **Organizations:** Valar Labs, Stanford University, Georgia Institute of Technology, Microsoft, PathAI, Curai, Boston Scientific, Capital One
- **Nationality:** American
- **Education:** B.S. in Biomedical/Medical Engineering, Georgia Institute of Technology, M.S. in Computer Science (AI/ML, Andrew Ng's group), Stanford University
- **Known for:** Forbes 30 Under 30 Healthcare 2025, Raised $26M total for Valar Labs ($4M seed + $22M Series A), Developed Vesta, first AI diagnostic for bladder cancer BCG therapy response, live at 20 U.S. hospitals with insurance coverage

## Career timeline

- **2017** — Graduated Georgia Tech with B.S. in Biomedical Engineering
- **2017–2018** — Computer Vision Scientist at Boston Scientific; ML Engineer at Capital One
- **2018** — Applied Scientist for Deep Learning at Microsoft, built Rewrite Suggestions feature in Microsoft Word
- **2019** — Deep Learning Researcher at PathAI (pathology AI) and Curai (telemedicine AI)
- **2019–2021** — Graduate Research Assistant at Stanford University under Prof. Pranav Rajpurkar (Andrew Ng's AI in Medicine group)
- **2021** — M.S. Computer Science from Stanford; co-founded Valar Labs with Damir Vrabac, Viswesh Krishna, and Prof. Pranav Rajpurkar
- **2022** — Valar Labs raises $4M seed round led by Andreessen Horowitz
- **2024** — Valar Labs raises $22M Series A led by DCVC and Andreessen Horowitz; launches Vesta for bladder cancer
- **2024** — Named to Forbes 30 Under 30 Healthcare 2025 list
- **2026** — Valar Labs publishes pivotal study in Journal of Clinical Oncology validating AI for pancreatic cancer chemotherapy response prediction

## Achievements

- Forbes 30 Under 30 Healthcare 2025
- Raised $26M total for Valar Labs ($4M seed + $22M Series A)
- Developed Vesta, first AI diagnostic for bladder cancer BCG therapy response, live at 20 U.S. hospitals with insurance coverage
- Published study in Journal of Clinical Oncology validating AI for pancreatic cancer chemotherapy response
- Co-authored research under Prof. Andrew Ng's AI in Medicine group at Stanford
- Built Microsoft Word's Rewrite Suggestions feature using deep learning sequence-to-sequence models
- Led validation study across 1,000+ patients at 12+ medical centers worldwide

## Latest updates

- **2026-02** — Valar Labs publishes pivotal study in Journal of Clinical Oncology on AI predicting chemotherapy response for pancreatic cancer patients
- **2024-12** — Anirudh Joshi named to Forbes 30 Under 30 Healthcare 2025 list
- **2024-05** — Valar Labs closes $22M Series A led by DCVC and Andreessen Horowitz; launches Vesta commercially at 20+ U.S. hospitals with insurance coverage

## Links

- Website: https://valarlabs.com
- LinkedIn: http://www.linkedin.com/in/anirudhjoshi95
- Twitter/X: https://twitter.com/anirrjoshi

---

Profile page: https://yespress.io/anirudh-joshi
Published by YesPress — https://yespress.io
Last updated: 2026-05-14